Rallybio Corporation (RLYB) News
Follow Rallybio Corporation (RLYB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Avenzo Therapeutics Closes Merger With Rallybio, Alongside $215 Million Placement
Avenzo Therapeutics announced the closing of its merger with Rallybio Corporation and referenced a previously announced $215 million concurrent private placement.
MNA | Nov 20, 2026, 09:30 PM UTC
L
Rallybio Announces Reverse Stock Split Tied to Proposed Avenzo Merger
Rallybio announced a reverse stock split of its common stock in connection with its proposed merger with Avenzo.
EQUITY | Nov 10, 2026, 10:15 PM UTC
M
Rallybio Reports $2.73 Million Net Loss for 2026
Rallybio reported no revenue and a net loss of $2.73 million in 2026, compared with revenue of $212,000 and net income of $16.02 million in the prior-year period. Diluted loss per share was $0.48, versus earnings per sha
EARNINGS | Oct 27, 2026, 12:11 PM UTC
L
Rallybio's Jonathan Lieber to shift to part-time CFO role
Jonathan Lieber will transition to part-time employment while remaining chief financial officer and principal financial officer, effective September 15, 2026.
EQUITY | Sep 09, 2026, 08:35 PM UTC